quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:16·296d
SECFiling
Inozyme Pharma Inc. logo

SEC Form EFFECT filed by Inozyme Pharma Inc.

INZY· Inozyme Pharma Inc.
Health Care
Original source

Companies

  • INZY
    Inozyme Pharma Inc.
    Health Care

Recent analyst ratings

  • Dec 12UpdateRaymond James$26.00
  • Sep 12UpdateStifel$16.00
  • Aug 13UpdateJefferies$17.00
  • May 30UpdateWells Fargo$14.00
  • Mar 23UpdateJefferies$6.00
  • May 26UpdateJefferies$5.00

Related

  • SEC280d
    Amendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.
  • SEC286d
    SEC Form 15-12G filed by Inozyme Pharma Inc.
  • INSIDER294d
    SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)
  • INSIDER294d
    COO Winton Matthew closing all direct ownership in the company (SEC Form 4)
  • INSIDER294d
    Director Bolte Axel closing all direct ownership in the company (SEC Form 4)
  • INSIDER294d
    SEC Form 4 filed by Director Sullivan Lynne Marie
  • INSIDER294d
    CEO & Chairman Treco Douglas A closing all direct ownership in the company (SEC Form 4)
  • INSIDER294d
    SEC Form 4 filed by Director Hopfner Robert Lorne
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022